Glycosmedia Weekly Diabetes News - 11/22/2019

Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People

In this cohort of transgender persons, insulin sensitivity but also post-OGTT incretin responses tend to increase with masculinization and to decrease with feminization (Diabetes Care)

Incretin‐based glucose‐lowering medications and the risk for acute pancreatitis and malignancies ‐ a meta‐analysis based on cardiovascular outcomes trials

Based on a large database of randomized, placebo‐controlled, prospective cardiovascular outcomes studies with GLP‐1 receptor agonists and DPP‐4 inhibitors, no signal for pancreatic cancer or any malignant neoplasms was detected. However, a 75% risk increase for development of an acute pancreatitis was seen in the meta‐analysis of DPP‐4 inhibitor CVOTs (Diabetes, Obesity and Metabolism)

Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes

The presence and number of microvascular complications should be considered in stratifying overall cardiovascular risk in type 1 diabetes (Cardiovascular Diabetology)

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes (NEJM)

Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents

Results from the International Diabetes Federation Diabetes Atlas, 9th edition (Diabetes Research and Clinical Practice)

Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045

Results from the International Diabetes Federation Diabetes Atlas, 9th edition (Diabetes Research and Clinical Practice)

Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events

These results suggest that liraglutide treatment is associated with reduced total MACE compared with placebo among patients with type 2 diabetes and high risk of cardiovascular events. This analysis supports the findings of an absolute benefit of liraglutide treatment with respect to the overall burden of cardiovascular events in this high-risk patient population (JAMA Cardiology)